Literature DB >> 25638467

The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia.

Cemil Bilir1, Huseyin Engin, Murat Can, Yasemin Bakkal Temi, Derya Demirtas.   

Abstract

We wanted to investigate the possible etiologic factors of cachexia. Forty-six patients diagnosed with cancer cachexia and 34 healthy controls were included in the study. Serum total testosterone, free testosterone, interleukin 1 (IL) alpha and beta, IL6, tumor necrosis factor (TNF) alpha, orexin, galanin, neuropeptide Y, tumor necrosis factor-like weak inducer of apoptosis and tumor necrosis factor receptor-associated factor 6, and C-reactive protein (CRP) levels were investigated. There were 36 male and 10 female patients in the cachexia group, and 24 male and 10 female patients in the control group. Median overall survival (OS) of the cachexia group after the diagnosis of cachexia was 8 (1-25) months. There were statistically significant relationships between OS and BMI, serum CRP, TRAF-6, albumin, and LDH levels in the cachexia group. In addition to cachexia, serum CRP, testosterone, and TNF alpha levels were statistically significantly correlated with OS in refractory cachexia. TRAF-6 levels was significantly correlated with type of cancer (P = 0.02). Although cachexia presents with a multifactorial ethio-pathogenesis, few of them affect the OS. Our novel results were that serum CRP, albumin, LDH, and TRAF-6 levels have a higher association with OS in patients with cancer cachexia compared to the many other parameters. An ongoing cachexia also called refractory cachexia is a recent definition. This end-stage term of cancer duration may be predicted by decreasing serum testosterone and increasing serum TNF alpha levels, as well as serum CRP levels.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25638467     DOI: 10.1007/s12032-015-0497-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  18 in total

1.  Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss.

Authors:  D C McMillan; W S Watson; P O'Gorman; T Preston; H R Scott; C S McArdle
Journal:  Nutr Cancer       Date:  2001       Impact factor: 2.900

2.  Leptin and neuropeptide Y plasma levels in children with cancer.

Authors:  Kudret Cağlar; Tezer Kutluk; Ali Varan; Zehra Koray; Canan Akyüz; Bilgehan Yalçin; Belkis Erbaş; Münevver Büyükpamukçu
Journal:  J Pediatr Endocrinol Metab       Date:  2005-05       Impact factor: 1.634

3.  [Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio- and chemotherapy].

Authors:  A Kowalczuk; A Wiecek; E Franek; F Kokot
Journal:  Pol Arch Med Wewn       Date:  2001-08

4.  Experimental study of the effect of IL-6 on cancer cachexia.

Authors:  T Ikeda; Y Nishiguchi; Y Chung; N Yamada; M Sowa
Journal:  Oncol Rep       Date:  1997 Sep-Oct       Impact factor: 3.906

5.  Nutritional deterioration in cancer: the role of disease and diet.

Authors:  P Ravasco; I Monteiro-Grillo; P M Vidal; M E Camilo
Journal:  Clin Oncol (R Coll Radiol)       Date:  2003-12       Impact factor: 4.126

6.  Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients.

Authors:  Ola Wallengren; Kent Lundholm; Ingvar Bosaeus
Journal:  Support Care Cancer       Date:  2013-01-13       Impact factor: 3.603

7.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

8.  Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients.

Authors:  Yuan-Shui Sun; Zai-Yuan Ye; Zhen-Yuan Qian; Xiao-Dong Xu; Jun-Feng Hu
Journal:  J Exp Clin Cancer Res       Date:  2012-09-26

Review 9.  Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  Nutr J       Date:  2010-12-22       Impact factor: 3.271

10.  Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention.

Authors:  Liying Gu; Lan Dai; Cong Cao; Jing Zhu; Chuanwei Ding; Hai-Bo Xu; Lihua Qiu; Wen Di
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

View more
  23 in total

Review 1.  Cancer- and cardiac-induced cachexia: same fate through different inflammatory mediators?

Authors:  Rita Nogueira-Ferreira; Fábio Sousa-Nunes; Adelino Leite-Moreira; Liliana Moreira-Costa; Rui Vitorino; Lúcio Lara Santos; Daniel Moreira-Gonçalves; Rita Ferreira
Journal:  Inflamm Res       Date:  2022-06-09       Impact factor: 6.986

Review 2.  Exercise as a therapy for cancer-induced muscle wasting.

Authors:  Jessica L Halle; Brittany R Counts; James A Carson
Journal:  Sports Med Health Sci       Date:  2020-12-03

3.  Tumor cell anabolism and host tissue catabolism-energetic inefficiency during cancer cachexia.

Authors:  Mangala Hegde; Uzini Devi Daimary; Sosmitha Girisa; Aviral Kumar; Ajaikumar B Kunnumakkara
Journal:  Exp Biol Med (Maywood)       Date:  2022-05-06

4.  Comparison of cachectic and non-cachectic sarcoma patients reveals an important role of Notch signaling in metastasis and myogenesis.

Authors:  Feiqi Lu; David Osei-Hwedieh; Jonathan B Mandell; Alejandro Morales-Restrepo; Margaret L Hankins; Jared A Crasto; Ruichen Ma; Vu Dinh; Rebecca J Watters; Kurt R Weiss
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

5.  Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer.

Authors:  Asta Bye; Nima Wesseltoft-Rao; Per Ole Iversen; Grete Skjegstad; Kirsten B Holven; Stine Ulven; Marianne J Hjermstad
Journal:  Med Oncol       Date:  2016-04-27       Impact factor: 3.064

6.  Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia.

Authors:  Roberto Mota; Jessica E Rodríguez; Andrea Bonetto; Thomas M O'Connell; Scott A Asher; Traci L Parry; Pamela Lockyer; Christopher R McCudden; Marion E Couch; Monte S Willis
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

Review 7.  Sarcopenia versus cancer cachexia: the muscle wasting continuum in healthy and diseased aging.

Authors:  Alexandra Moreira-Pais; Rita Ferreira; Paula A Oliveira; José A Duarte
Journal:  Biogerontology       Date:  2021-07-29       Impact factor: 4.277

8.  Is Serum Total LDH Evaluation Able to Differentiate between Alimentary Lymphoma and Inflammatory Bowel Disease in a Real World Clinical Setting?

Authors:  Rossella Terragni; Antonio M Morselli-Labate; Massimo Vignoli; Enrico Bottero; Barbara Brunetti; Jimmy H Saunders
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

9.  Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways.

Authors:  Guohua Zhang; Zhelong Liu; Hui Ding; Hongyu Miao; Jose M Garcia; Yi-Ping Li
Journal:  Sci Rep       Date:  2017-05-23       Impact factor: 4.379

Review 10.  Cancer Cachexia and MicroRNAs.

Authors:  Rodolfo Gonzalez Camargo; Henrique Quintas Teixeira Ribeiro; Murilo Vieira Geraldo; Emídio Matos-Neto; Rodrigo Xavier Neves; Luiz Carlos Carnevali; Felipe Fedrizzi Donatto; Paulo S M Alcântara; José P Ottoch; Marília Seelaender
Journal:  Mediators Inflamm       Date:  2015-10-04       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.